Back to Hematology
Hematologyv1977Evidence-Based

Binet Staging System for Chronic Lymphocytic Leukemia (CLL)

Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions

Clinical Input Parameters

g/dL
Range: 3 — 20 g/dL
×10³/mm³
Range: 10 — 1000 ×10³/mm³
Clinical Assessment
Awaiting Parameters
binet stage
—stage
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Count lymphoid areas involved (cervical, axillary, inguinal, spleen, liver). Stage A: <3 areas + normal Hgb/platelets. Stage B: ≥3 areas + normal Hgb/platelets. Stage C: Anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelets <100×10³/mm³)

Clinical Pearls & Practice Notes

  • The Binet system is the European standard for CLL staging, comparable to the American Rai system
  • Five lymphoid areas are assessed: cervical, axillary, inguinal lymph nodes, plus spleen and liver
  • Anemia is defined as hemoglobin <10 g/dL (100 g/L)
  • Thrombocytopenia is defined as platelet count <100×10³/mm³ (100×10⁹/L)
  • Stage C has the worst prognosis regardless of number of lymphoid areas involved
  • Modern molecular markers (17p deletion, TP53 mutations, IGHV status) provide additional prognostic information
  • Survival estimates may be improved with modern targeted therapies
  • Both Binet and Rai systems are simple, reproducible, and require only physical examination and basic labs
  • Treatment decisions should incorporate clinical symptoms, performance status, and comorbidities

Evidence & Literature Citations

  1. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206.
  2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760.
  3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34.

Score Interpretation Ranges

Stage A1 – 1 pts

Low risk - <3 lymphoid areas involved, normal Hgb and platelets

Stage B2 – 2 pts

Intermediate risk - ≥3 lymphoid areas involved, normal Hgb and platelets

Stage C3 – 3 pts

High risk - Anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelets <100×10³/mm³)

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.